Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
Fadi Khreish, Niklas Kochems, Florian Rosar, Amir Sabet, Martin Ries, Stephan Maus, Matthias Saar, Mark Bartholomä, Samer Ezziddin
Topics & Concepts
MedicineProstate cancerInternal medicineConfidence intervalProportional hazards modelOncologyProgressive diseaseUrologyRegimenLog-rank testGastroenterologyCancerDiseaseProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsPeptidase Inhibition and Analysis